source · text/markdown
source_60574f4a6cc94e5e
sha256 e5a2c12e7f3f877678a9edd4d2e6782c40eacde0d07644bab070d600545c3a34
by researka:v2 · 2026-06-27 08:24:15.896706+04:00
# Hypothesis-Generating Brief: Zone 2 training — full paper ## Abstract Evidence-honesty note: 46/55 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. Zone 2 training, characterized by sustained sub-lactate-threshold aerobic work, has attracted interest as a longevity-oriented modality, yet the comparative evidence base against moderate-intensity continuous training (MICT) and high-intensity interval training (HIIT) spans cardiometabolic, muscle-function, and contextual outcomes across more than 50 curated studies. Across the corpus, the curated evidence does not yet support a uniform superiority claim for any single intensity zone: HIIT outperforms MICT for selected cardiometabolic and body-composition endpoints in adolescents, cancer survivors, and CAD patients, but the same trials show no advantage, or reversal, in prediabetes, chronic low back pain, and select elderly cohorts. Because most context-specific signals rest on indirect or observational evidence and the few direct RCTs disagree on directional effect, the clinical case for Zone 2 training as an anti-aging intervention remains incomplete; mechanistic plausibility coexists with mixed human data, and population-specific boundary conditions still need to be defined in adequately powered head-to-head trials. **Evidence-abstraction note.** The 55 retained reference papers are not 55 independent primary clinical trials: 46 are review, indirect, mechanistic, or registered-protocol source-level summaries, and 9 are classified as direct interventional evidence. Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence. ## Introduction Population aging is reshaping the priorities of clinical medicine, and the question of whether healthspan can be meaningfully extended through scalable, low-burden interventions has moved to the center of the geroscience agenda. The clinical stakes are concrete: multi-morbidity accrues with age, polypharmacy is the rule rather than the exception in those over 65, and the marginal cost-effectiveness of adding yet another disease-specific drug diminishes as the count of accumulated conditions grows. Against this backdrop, attention has turned toward interventions that target aging biology itself rather than any single chronic disease. The premise is straightforward — if the rate of biological aging can be slowed, multiple downstream conditions might be postponed together, and the cumulative disability burden across a lifetime compressed. This synthesis takes that question seriously for one specific candidate intervention, Zone2, defined here as moderate-intensity continuous aerobic exercise delivered within a defined, ecologically accessible training band. The motivating concern is that the public-health case for any anti-aging therapy rests on evidence that is both mechanistically credible and translationally robust, and evidence suggests that for Zone2 the two halves of that equation have not yet been independently settled. The Zone2 question is therefore not whether exercise is healthful — that has been demonstrated across many populations — but whether this specific intensity-domain prescription, applied over realistic durations in heterogeneous adults, performs as an aging-targeted intervention with reproducible clinical benefits. The answer matters because Zone2 is one of the few candidate interventions that is essentially free, has no regulatory gatekeeping burden, and could plausibly be deployed at population scale if the evidence supports it. The geroscience hypothesis underlying the present synthesis rests on the proposition that the major chronic diseases of late life share a finite set of upstream biological drivers — mitochondrial dysfunction, chronic low-grade inflammation, cellular senescence, dysregulated nutrient sensing, and altered intercellular communication — and that modulating these drivers could in principle delay the onset of multiple age-related conditions simultaneously. Within this framework, exercise modalities such as Zone2 are positioned as candidate geroprotectors, alongside pharmacological candidates and dietary restriction mimetics, because they engage several of the same upstream pathways, including mitochondrial biogenesis, insulin sensitivity, and inflammatory tone. The methodological question this raises is whether such mechanistic plausibility is sufficient evidence on which to base a public-health recommendation, or whether Zone2 must instead be evaluated on its own terms, against the same hard-outcome standards applied to any candidate anti-aging drug. The repurposing-versus-novel-development distinction is particularly sharp here: unlike newly developed geroprotectors that require de novo safety profiling and dose-finding, Zone2 draws on a substantial pre-existing behavioral and clinical safety base, but it also lacks the standardized dosing, quality-controlled delivery, and outcome standardization that a pharmaceutical development program would impose. Whether the lack of standardization constitutes an obstacle or a feature remains an open question, and one that the present evidence base for Zone2 is poorly positioned to resolve on its own. Importantly, the geroscience framing does not require that Zone2 reverse aging — only that it slow one or more measurable axes of biological or functional decline, and that this slowing be observable in human cohorts under realistic deployment conditions. Zone2 belongs to the broader drug class — using the term loosely for an intervention category — of exercise-based modalities, which in clinical research have historically been operationalized as moderate-intensity continuous training (MICT) defined by a target heart-rate or oxygen-uptake band, typically delivered across 30-60 minute sessions and repeated two to four times per week. The mechanism most often invoked for Zone2 is enhancement of mitochondrial oxidative capacity, substrate oxidation efficiency, and capillary density in working skeletal muscle, with downstream effects on systemic cardiometabolic risk markers such as blood pressure, lipid profile, glycemic control, and cardiorespiratory fitness expressed as peak oxygen uptake. Regulatory and clinical history matter for the question at hand: exercise interventions sit outside the formal drug-approval pathway and have instead accumulated evidence through decades of small-to-medium physiological and rehabilitation studies, supplemented in recent years by larger trials in cardiac rehabilitation, type 2 diabetes management, cancer survivorship, and post-stroke recovery. Access is essentially universal, in the sense that no prescription is required, but adherence is notoriously variable and dose-response is poorly defined compared with pharmacological agents. The source-grounded reality is that the Zone2 literature is dominated by comparisons against higher-intensity alternatives such as high-intensity interval training and sprint interval training, not by dose-finding studies of Zone2 against a true no-intervention control or against lower-intensity comparators — a structural feature of the evidence base that complicates any clean estimate of Zone2's independent effect on aging biology. The question of whether Zone2 is the active therapeutic ingredient, or merely the convenient comparator arm against which more novel modalities are tested, has been proposed as a central interpretive challenge for the field. Despite the breadth of the available trials, several unresolved questions cloud the interpretation of Zone2 as an aging-targeted intervention. The first is mechanism-to-function translation: even where Zone2 produces measurable changes in intermediate biomarkers such as lipid oxidation or cardiorespiratory fitness, the linkage of those changes to durable shifts in healthspan or lifespan remains largely inferential. The second is population specificity — whether the cardiometabolic benefits observed in coronary artery disease patients, the glycemic improvements seen in type 2 diabetes cohorts, and the functional gains documented in stroke survivors can be aggregated into a single coherent estimate of effect on aging biology, or whether the field is observing a federation of distinct clinical effects rather than a unified geroprotective signal. The third is duration: most trials run between 8 and 16 weeks, with follow-up rarely extending beyond 12 months, so the question of whether Zone2-induced adaptations persist, attenuate, or amplify over the multi-year timescales relevant to aging remains effectively open. The fourth is dose-response: the existing trials compare a narrow band of Zone2 doses against higher-intensity alternatives, leaving the lower edge of the dose-response curve — including the question of whether very low doses of Zone2 retain meaningful effect — under-characterized. The fifth is tradeoff structure: the comparative literature provides signals on adherence, enjoyment, dropout, and safety, but these signals are inconsistently reported and sometimes conflict across studies, and any honest synthesis must acknowledge that the Zone2 tradeoff profile has not been mapped with the same precision as that of pharmacological geroprotector candidates. ## Background The background evidence for Zone 2 training is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Liu 2026, Goncalves 2023, Goncalves 2024 are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation. The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect. Across the retained sources, positive signals cluster around the contextual adjacent evidence, cardiometabolic, safety and comorbidity outcome classes; null signals around the contextual adjacent evidence, safety and comorbidity, cardiometabolic outcome classes; and negative or adverse signals around the contextual adjacent evidence and cardiometabolic outcome classes. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation. Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end. Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence. This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another. The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty. The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support. No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record. ## Methods ### Review type and protocol This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-zone2_training-v06-DAILY-2026-06-27T04-09-53Z`. ### Information sources Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-27. ### Search strategy The following topic-anchored queries were executed against the information sources listed above: - `moderate-intensity continuous training AND older adults` - `low-intensity aerobic training AND aging AND trial` - `zone 2 training AND metabolic health` - `MICT AND older adults AND VO2max` - `endurance base training AND insulin sensitivity` ### Eligibility criteria - Sources whose primary content addresses zone2 training. - Sources with extractable quantitative or qualitative findings. - Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable. - Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle). ### Selection of sources of evidence The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 224 records in the receipt-candidate union, 68 were classified as source candidates and 55 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission. ### source admission funnel | Admission bucket | n | |---|---:| | Receipt candidate union | 224 | | Classified source candidates | 68 | | No extractable claims | 19 | | None-only claim binding | 5 | | Mixed partial-or-none claim-binding candidates | 75 | | Partial-only claim-binding candidates | 29 | | Strict high-confidence sources | 28 | | Admitted final sources | 55 | ### Exclusion reasons - No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus. ### Data items The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text. ### Risk-of-bias appraisal Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification. ### Synthesis approach Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, muscle function, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates. ### AI-use disclosure Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified. ### Accountability Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review. ## Results | Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation | |---|---|---|---|---| | Zone 2 training / Contextual Adjacent Evidence | n=34; claims=3091 | significant source statistic in 30/34 sources; receipt-level direction coded unclear | 7 direct; 15 indirect; 1 protocol; 11 review | limited corpus depth in this outcome class | | Zone 2 training / Cardiometabolic | n=11; claims=1126 | significant source statistic in 9/11 sources; receipt-level direction coded unclear | 1 direct; 2 indirect; 8 review | limited corpus depth in this outcome class | | Zone 2 training / Muscle Function | n=8; claims=505 | significant source statistic in 6/8 sources; receipt-level direction coded unclear | 1 direct; 1 indirect; 6 review | limited corpus depth in this outcome class | | Zone 2 training / Safety and Comorbidity | n=2; claims=100 | positive signal in 1/2 sources | 1 indirect; 1 review | limited corpus depth in this outcome class | **Source-context map:** Source-title contexts are separated for interpretation and are not pooled as one clinical effect. - Aging and geroscience context: 5 sources; significant source statistic in 4/5 sources; receipt-level direction coded unclear. - Oncology and cancer context: 2 sources; positive signal in 2/2 sources. - Pulmonary and rare-disease context: 2 sources; significant source statistic in 2/2 sources; receipt-level direction coded unclear. - Skeletal and muscle context: 2 sources; significant source statistic in 2/2 sources; receipt-level direction coded unclear. - Dosing and pharmacokinetics context: 1 sources; significant source statistic in 1/1 sources; receipt-level direction coded unclear. - Transplant and fibrosis context: 1 sources; significant source statistic in 1/1 sources; receipt-level direction coded unclear. **Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim. ### Results Summary - Contextual Adjacent Evidence: n=34; claims=3091; mixed signal in 15/34 sources | directness: 7 direct; 15 indirect; 11 review; 1 protocol; main limitation: directionally heterogeneous. - Cardiometabolic: n=11; claims=1126; mixed signal in 5/11 sources | directness: 1 direct; 2 indirect; 8 review; main limitation: directionally heterogeneous. - Muscle Function: n=8; claims=505; mixed signal in 5/8 sources | directness: 1 direct; 1 indirect; 6 review; main limitation: directionally heterogeneous. - Safety and Comorbidity: n=2; claims=100; benefit signal in 1/2 sources | directness: 1 indirect; 1 review; main limitation: no direct clinical anchor. ### Cardiometabolic Outcomes The cardiometabolic evidence corpus is anchored by a single direct clinical RCT and a dense cluster of indirect cohort data and reviews. Quantitative findings across the indirect cohort and review evidence are catalogued in detail in the evidence synthesis, which preserves every study × p-value tuple. B 2024, a systematic review of HIIT versus MICT on vascular function in 346 individuals with overweight and obesity, contributed no individual p-values but framed the indirect mechanistic substrate. Further cardiometabolic contrasts appear in Guo 2023, Li 2022b, Liang 2026, Li 2026, and the sedentary-blood-pressure-reactivity review (Effects of High-Intensity Interval 2025). Li 2026, focused on adults with prediabetes, contributed no p-values but concluded that MICT showed a small but statistically significant advantage over HIIT on cardiometabolic risk factors. Mechanistically, the cardiometabolic signal integrates directly measured clinical RCT evidence (Goncalves 2024) with mechanistic human studies (Zhang 2025a on metabolic flexibility, Sun 2024 on cardiometabolic risk factors in adolescents) and preclinical-style indirect cohort and review data (B 2024, Liang 2024, Li 2025a, Guo 2023, Li 2022b, Liang 2026, Li 2026, Effects of High-Intensity Interval 2025), all consistent with vascular, metabolic, and blood-pressure pathways responsive to training intensity. Guo 2023 also conflicts with Effects of High-Intensity Interval 2025 (null), and Li 2022b (positive) conflicts with Effects of High-Intensity Interval 2025 (null), each at severity 4. The indirectness gap is recurrent: the direct clinical RCT Goncalves 2024 sits alongside nine indirect or review syntheses (Effects of High-Intensity Interval 2025, Guo 2023, Liang 2024, Sun 2024, B 2024, Zhang 2025a, Li 2025a, Liang 2026, Li 2026, Li 2022b), and these evidence layers can be interpreted as complementary rather than substitutive. ### Contextual Adjacent Evidence Outcomes The 'contextual other' outcome class subsumes the heterogeneous cluster of cardiorespiratory, metabolic, body-composition, cognitive, and quality-of-life endpoints collected across the corpus, with the integrating RCT evidence concentrated in six trials. Liu 2026 randomized adolescents with overweight/obesity to high-intensity functional training versus moderate-intensity continuous training and reported multiple within-group p-values reaching P < 0.001, P = 0.013, P = 0.002, P = 0.037, P = 0.044, P = 0.689, P = 0.036, and P = 0.016, alongside between-condition contrasts of P = 0.069, P = 0.027, P = 0.023, P = 0.001, P = 0.117, P = 0.380, P = 0.530, P < 0.05, P < 0.01, P = 0.009, P = 0.1, and P = 0.071 across body-composition, fitness, and psychological endpoints. The two studies establish that HIIT/MICT comparisons in direct RCT designs produce a mixture of clearly significant and clearly null within-condition contrasts even within a single trial, illustrating the granularity concealed by aggregate direction codes. A second cluster of direct RCTs extends the contextual other mapping to cardiometabolic and post-event populations. Mechanistically, the contextual other evidence base spans clinical RCT, mechanistic human, and indirect observational streams that converge on aerobic, metabolic, and substrate-utilization pathways without producing a uniform direction. Across mechanistic human and indirect observational streams the picture is therefore one of overlapping but non-identical physiological signatures, with substrate oxidation, lactate handling, and lipidomic remodeling differentiating modalities while whole-body aerobic endpoints frequently converge. Within-corpus tensions on 'contextual other' are dense and must be read against effect direction and directness rather than collapsed to a single verdict. Neuendorf 2023 (positive review) and Peng 2025 (positive meta-analysis) agree with Rohmansyah 2023, while Chu 2026 (positive in healthy elderly) adds a third positive review-level signal; these three positive reviews sit against Gu 2023 (null in heart failure), Luo 2024 (null in overweight/obese), Feng 2025 (null in endurance runners), Ahmad 2025 (null protocol in prehabilitation), and Zhao 2025 (null in polycystic ovary syndrome), producing a high-severity null vs positive pattern across review-level evidence. By contrast, Neuendorf 2023 (positive) is in direct conflict with Gao 2025 (negative), and Peng 2025 (positive) conflicts with Gao 2025 (negative); Chu 2026 (positive) likewise conflicts with Li 2022a (negative), and Gao 2025 plus Li 2022a agree on a negative reading. Direct RCTs (Nikoletou 2023, Yu 2023b, Goncalves 2023, Goncalves 2025, Chen 2025, Liu 2026, Lapointe 2023) repeatedly diverge in effect direction from indirect or review-level signals on the same outcome class, so the 'contextual other' verdict cannot be resolved without stratifying by population, modality fidelity, and directness of endpoint. ### Muscle Function Outcomes Eight curated references populate the muscle function outcome class, spanning one direct clinical RCT, several systematic reviews and meta-analyses, and a mechanistic mitochondrial-dynamics study. Jung 2020, a randomized trial in adults, examined one year of free-living HIIT versus MICT on cardiorespiratory fitness (CRF) and accelerometer-measured physical activity and reported a key between-group comparison at P = 0.018, providing the only direct-exercise-trial anchor for this outcome class. The remaining evidence base is dominated by pooled syntheses: Yu 2023a (NCT02916225), Zheng 2025, Li 2025b, Effects of High-intensity Interval 2023, B Compare the Effects 2025, Effectiveness of High-intensity Interval 2024, and Impact of Low-Volume High-Intensity 2024, each contributing indirect or review-level estimates of how interval versus continuous training modifies functional endpoints. The quantitative findings are heterogeneous. Impact of Low-Volume High-Intensity 2024, restricted to postmenopausal women, reported predicted VO2max gains that were statistically and practically significant after HIIT (P = 0.01), with non-significant comparator effects (P > 0.05). B Compare the Effects 2025 found between-group superiority for MICT over Pilates in hypertensive patients, including VO2max mean difference = 8.62 ml/kg/min (P < 0.001). By contrast, Effects of High-intensity Interval 2023 in permanent/persistent atrial fibrillation patients showed clinically meaningful VO2max increases in only two HIIT participants (15.4%) and two MICT participants (20.0%), with the review narrative signaling a null overall pattern. Mechanistically, Li 2025b supplies a human mechanistic substrate for the muscle function findings by linking interval versus continuous training to altered mitochondrial dynamics in adult skeletal muscle, with multiple mitochondrial-fission/fusion and respiratory-complex comparisons reaching P < 0.05 (e. For example, P = 0.041, P = 0.047, P < 0.001) and several non-significant comparisons (P = 0.61, P = 0.081, P = 0.75). The clinical RCT anchor (Jung 2020) operationalizes MICT in a free-living setting and detects a between-group CRF difference at P = 0.018, while the pooled clinical reviews (B Compare the Effects 2025; Impact of Low-Volume High-Intensity 2024) provide group-mean functional contrasts at P < 0.001 and P = 0.01 respectively. Together, the mechanistic human studies and clinical RCT/review evidence triangulate the mitochondrial and cardiorespiratory pathways most plausibly engaged by zone-2-equivalent continuous work. Within the muscle function class, two named tensions dominate. First, a partial conflict emerges between Impact of Low-Volume High-Intensity 2024, which reports a positive HIIT effect on predicted VO2max (P = 0.01) in postmenopausal women, and Effects of High-intensity Interval 2023, which finds a null pattern in atrial fibrillation patients, with only 15.4% of HIIT and 20.0% of MICT participants reaching clinically meaningful gains. This mismatch between a single direct trial and a broader indirect evidence base leaves the magnitude — and even direction — of zone-2-relevant muscle function effects contingent on the clinical context in which they are measured. ### Safety and Comorbidity Outcomes Within the curated evidence base for zone 2 training, two observational cohorts dominate the safety comorbidity outcome class and provide the empirical anchor for this subsection. Moon 2025 enrolled twenty-nine higher-functioning, ambulatory chronic stroke survivors and randomized them to either high-intensity interval training (HIIT, n=15) or moderate-intensity continuous training (MICT, n=14), framing safety and comorbidity tolerance as primary endpoints in a population whose cardiovascular reserve is intrinsically compromised by prior cerebrovascular injury. Cerini 2022, by contrast, was a randomised single-blinded feasibility study in chronic low back pain subjects comparing 12 weeks of HIIT versus MICT, and was explicitly designed and reported as a review-grade feasibility investigation rather than as a definitive superiority or non-inferiority trial. Both cohorts therefore speak to safety comorbidity in clinically vulnerable populations, but they do so from materially different design positions and with materially different statistical power for adverse-event inference, a structural asymmetry that the remainder of this subsection unpacks. Quantitative findings diverge sharply between the two cohorts on the central safety comorbidity question. Across the corpus, the two cohorts operationalize the within-corpus tension flagged in the cross-study disagreement map as null vs positive with severity 4: one small randomized cohort shows multiple significant safety-relevant contrasts favoring higher-intensity work, while a feasibility-grade cohort in a different comorbidity shows uniformly null between-group differences with high and comparable adherence in both arms. Mechanistically, the divergence between Moon 2025 and Cerini 2022 maps onto the substrate-level distinction between intensity-stratified cardiovascular stress and intensity-stratified musculoskeletal tolerance, even though both studies nominally compare HIIT to MICT in chronic disease. Moon 2025's population carries a primary lesion in the cerebrovascular bed, so any signal on safety comorbidity is read against background impairments in cerebral autoregulation, vascular reactivity, and locomotor reserve, and the p-values of P = 0.001, P = 0.002, P = 0.004, P < 0.05, and P < 0.001 are interpreted in a clinical RCT context in which higher-functioning chronic stroke survivors appear to tolerate, and arguably benefit from, interval-based cardiovascular loading relative to steady-state work. The mechanistic substrate therefore separates cleanly along organ system: cardiovascular reserve versus axial musculoskeletal tolerance. Read together, the two cohorts suggest that the safety comorbidity case for zone 2 training — and for the broader HIIT-versus-MICT comparison that frames it — is context-dependent in the precise sense flagged by the picked thesis: positive signals coexist with null findings, and the boundary conditions (cerebrovascular reserve versus axial musculoskeletal tolerance, higher-functioning versus feasibility-eligible, randomized versus review-graded) remain the operative variables, not the intensity label itself. ## Cross-Domain Synthesis The most consequential cross-outcome tension in the Zone2 corpus is the disagreement on cardiometabolic endpoints between two review-grade syntheses of hypertension and cardiometabolic cohorts: Li 2022b reports a positive effect of moderate-intensity continuous training on blood pressure in hypertensive patients (a within-MICT signal rather than a HIIT-vs-MICT contrast), whereas Guo 2023 reports a negative pooled effect of HIIT vs. MICT on cardiorespiratory fitness and fat loss in young and middle-aged adults. The mechanism-level disagreement is plausible because the two reviews pool different design templates: Li 2022b isolates a single clinical endpoint (BP) in a hypertensive population where MICT serves as the active comparator of interest, whereas Guo 2023 aggregates VO2max and fat-loss outcomes from young/middle-aged cohorts where HIIT dose, interval length, and weekly volume differ markedly. The boundary condition is therefore population- and endpoint-specific — MICT appears sufficient and well-tolerated for blood pressure reduction in hypertension (Li 2022b), while for fat loss and CRF in healthy younger adults the incremental HIIT signal can erode or even invert relative to MICT (Guo 2023). To resolve the conflict, future work would need to (a) stratify by baseline cardiovascular risk (hypertensive vs. normotensive) and (b) harmonize the HIIT dose so that review-level pooling does not conflate sprint protocols with submaximal intervals, which the corpus currently does. A second, equally load-bearing tension spans the 'contextual other' outcome class, where Neuendorf 2023 (positive) and Gao 2025 (negative) reach opposing pooled conclusions on functional performance and capacity outcomes in cancer and coronary artery disease populations respectively. The disagreement cannot be interpreted as a clean contradiction of Zone2 versus HIIT, because the two reviews enroll fundamentally different patient substrates: Neuendorf 2023 covers cancer patients whose functional endpoints (walking distance, fatigue) are highly responsive to any aerobic stimulus, whereas Gao 2025 covers CAD patients in whom peak VO2 ceilings are constrained by coronary supply and where HIIT and MICT often converge on hard outcomes. The boundary condition is therefore diagnosis-driven — when the dominant limitation is deconditioning (cancer rehabilitation), both MICT and HIIT tend to outperform usual care (Neuendorf 2023, positive), whereas in established CAD, the comparative advantage narrows and may flip depending on how reviewers code the comparator (Gao 2025, negative). What would resolve the tension is patient-level meta-analysis stratifying on baseline VO2max and on whether HIIT protocols reached ≥85% HRpeak — a granular cut the current corpus cannot supply. A subtler but pervasive tension is the mechanism-vs-clinical split that runs across the entire RCT-vs-review axis, exemplified by Nikoletou 2023 (a direct human RCT pilot in interstitial lung disease reporting positive exercise-capacity trends on the 6MWD) versus the broader review syntheses on muscle function and cardiometabolic endpoints (Zheng 2025, Li 2025a, Li 2022b). Mechanistic plausibility — that submaximal continuous work drives mitochondrial biogenesis, capillary density, and lipid oxidation in skeletal muscle — is well established in indirect exercise-physiology literature, but the matched human RCTs at clinical endpoints are small, short, and frequently underpowered for the hard outcomes that matter to patients (VO2max, 6MWD, BP). Per Ioannidis 2005, surrogate physiological adaptations cannot be equated with hard-outcome validity, and the Zone2 literature exemplifies this gap: the positive biological signals in mitochondrial dynamics and metabolic flexibility are not yet matched by RCT evidence on hospitalization or mortality. The boundary condition is therefore one of evidentiary hierarchy — mechanistic RCTs (e. For example, Nikoletou 2023) should be cited as supportive but not as substitutes for clinical-endpoint meta-analyses (Zheng 2025, Li 2025a), and the field would advance most by pre-registering hard-outcome trials with adequate follow-up. Another tension concerns the safety comorbidity outcome class, where Moon 2025 reports positive cardiovascular and functional outcomes for HIIT vs. MICT in higher-functioning chronic stroke, whereas Cerini 2022 reports null differences in adherence and feasibility between HIIT and MICT in chronic low back pain. The boundary condition is therefore the dominant impairment mechanism — neurologic vs. musculoskeletal vs. pain-driven — and the resolving evidence would be a head-to-head RCT in each population stratified by baseline functional reserve, using Tinetti 1988-type fall-prevalence endpoints for the neurologic arm and pain-related disability for the musculoskeletal arm. A final, integrative tension runs through the muscle function outcome class and connects the surrogate-endpoint literature to functional performance: Li 2025b (positive on mitochondrial dynamics in human skeletal muscle) and Yu 2023a (no statistically significant differences on quality-of-life physical component summary between HIIT and MICT in cardiovascular disease patients) sit on opposite sides of the surrogate-vs-functional divide. The mechanism-level reading is that MICT and HIIT both elicit measurable mitochondrial remodeling in trained muscle (Li 2025b), yet when the same contrast is read against patient-reported physical function, the differences attenuate or vanish (Yu 2023a). The boundary condition is therefore the level of measurement: at the tissue level, adaptations are visible; at the patient-reported level, they wash out — a pattern that the broader Zone2 literature treats as evidence of equivalence rather than as evidence of efficacy. To resolve this, the field needs trials that pre-specify a minimally important difference on the physical-component summary and are powered to detect it, rather than reporting null results as definitive equivalence. ### Boundary-condition synthesis We operationalize a Metabolic-Functional Tradeoff framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes. The included evidence base contains direct, indirect evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict. The framework is useful here because the matrix contains mechanism-vs-clinical, null-vs-positive, null-vs-negative tensions that can otherwise be mistaken for simple inconsistency. A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework. This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support. ## Discussion **Thesis:** Across 55 curated reference papers, the evidence base for Zone2 shows a context-dependent profile. Positive signals appear in: 'contextual other', cardiometabolic. Negative signals appear in: 'contextual other', cardiometabolic. Null findings dominate: 'contextual other', safety comorbidity. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Zone2 anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile. The interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers. ### Evidence Summary The evidence base for this synthesis comprises 55 included sources. The evidence-tier distribution is: B2 (n=33), B1 (n=12), A1 (n=9), D1 (n=1). By directness, the breakdown is: review (n=26), indirect (n=19), direct (n=9), protocol (n=1). 47 of 55 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight. Populations covered span 3 distinct summaries across the source set: adults; older adults; type 2 diabetes patients. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from. ### Interpretation constraints The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work. The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately. The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away. The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven. The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript. This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic. Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations. **Resolution criteria:** This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile. ## Limitations **Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim. First, the corpus cannot support claims that extend beyond its enrollment scope. No trial in the curated evidence base follows a healthy non-diabetic adult cohort for the duration needed to detect hard endpoints such as cardiovascular mortality, incident heart failure, or all-cause mortality, and the longest follow-ups visible in the sources (e. For example, the 1-year observation window in Jung 2020, with only P = 0.018 reported for the single between-group contrast) are far too short to anchor longevity or disease-prevention conclusions. The cardiometabolic reviews in this set (Li 2022b, Liang 2024, Guo 2023, Liang 2026, Effects of High-Intensity Interval 2025, Li 2026) report only intermediate biomarkers — blood pressure (Li 2022b), cardiorespiratory fitness (Guo 2023, Liang 2026), and glycemic indices (Li 2026) — so any extrapolation from these biomarkers to mortality reduction is, in the language of Ioannidis 2005, a surrogate-to-hard-outcome inference that the corpus itself does not test. Finally, the population labels in the sources (adults, older adults, type 2 diabetes patients, adolescents with obesity) do not cover non-diabetic middle-aged adults — a population central to preventive cardiology — and so the headline conclusions about zone-2 training's role in primary prevention cannot be supported from these data. Second, several clinically interesting outcomes are supported by only a single source and therefore cannot be replicated within the corpus. For each of these endpoints the absence of a second within-corpus trial means the headline cannot be defended against a plausible null result, and the synthesis is structurally dependent on the one positive study for that outcome. This is a corpus-internal replication deficit, not a literature-wide one, and it directly limits which mechanism-to-clinic claims can be made with any defensibility. Fifth, a non-trivial mechanism-to-clinic gap exists for several biologically attractive claims. Together these gaps mean the mechanistic plausibility story is real, but the within-corpus clinical link is incomplete. Sixth, the corpus shows substantive disagreement that the synthesis cannot resolve internally. On contextual other outcomes, Gao 2025 reports a negative direction while Peng 2025, Rohmansyah 2023, Neuendorf 2023, and Chu 2026 all report positive directions — a direct conflict that the cross-domain synthesis flags but cannot explain from within-corpus data. The only resolution available is external literature, and the synthesis has no method to import that resolution. The protocol-only record Ahmad 2025 has not yet generated results, which means the prehabilitation-in-major-abdominal-surgery endpoint is structurally undecidable at the time of this synthesis. These unresolved conflicts are not limitations of analysis but limitations of the curated evidence base: the corpus simply does not contain the head-to-head trial that would settle them, and the synthesis can only describe the disagreement, not adjudicate it. ## Conclusion Across the 55 curated references, the Zone2 evidence base shows a context-dependent profile in which positive cardiometabolic and contextual signals coexist with null and negative findings on the same outcome classes, and the boundary conditions for any anti-aging inference remain to be established. We therefore conclude that the evidence supports a hypothesis that MICT-class zone2 work contributes meaningfully to general cardiometabolic health, but it does not yet establish Zone2 as a validated standalone anti-aging intervention, and mechanistic plausibility cannot be substituted for hard-outcome confirmation. The evidence tiers are B2 (n=33), B1 (n=12), A1 (n=9), D1 (n=1), and directness is review (n=26), indirect (n=19), direct (n=9), protocol (n=1). Effect directions are unclear (n=25), mixed (n=9), positive (n=9), null (n=9), negative (n=3), with 47 sources carrying source-traced p-values and 465 documented cross-source tensions. These counts define the ceiling for the paper's claim strength: the conclusion can identify where the corpus is coherent, but it cannot turn indirect, heterogeneous, or mixed evidence into a clinical recommendation. The closing inference should therefore follow the evidence map rather than the topic label. Direct human sources carry the most weight when they measure clinically proximate outcomes in the population under review. Indirect clinical sources, reviews, mechanistic papers, and protocols remain useful, but they define context, plausibility, and uncertainty rather than proof of effect. Where directions conflict, the safer conclusion is that design, endpoint, eligibility, comparator, or follow-up differences may be controlling the signal. Where findings are null or mixed, those results remain part of the answer because they limit how far a positive or mechanistic claim can travel. The practical takeaway is bounded and revisable. The paper can be interpreted as a source-traced map of what the current source set can support, not as a treatment guideline or a pooled efficacy claim. A stronger future conclusion would require aligned direct evidence, durable endpoints, and fewer unresolved cross-source tensions. Until then, the responsible conclusion is to preserve uncertainty, state the strongest supported signal narrowly, make the remaining research gaps visible, and keep downstream reuse tied to the same source-level limits. ## What This Synthesis Adds This synthesis maps 55 included sources on Zone2 Training across 4 outcome classes and a high-density pairwise disagreement map. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit. The strongest unresolved contrast is the disagreement between Guo 2023 and Li 2022b on cardiometabolic (severity 5/5), which defines the boundary condition future studies must test rather than smooth over. Prior reviews in the corpus (Liang 2024, Li 2025a, Peng 2025, Chu 2026, Li 2022b) emphasize convergent signals on Zone2 Training. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary. ### Boundary-Condition Matrix | Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary | |---|---:|---:|---|---| | cardiometabolic | 1 | 10 | mixed, negative, null, positive, unclear | conflict-resolution gap | | muscle function | 1 | 7 | mixed, null, positive, unclear | conflict-resolution gap | | safety and comorbidity | 0 | 2 | null, positive | conflict-resolution gap | | contextual adjacent evidence | 7 | 27 | mixed, negative, null, positive, unclear | conflict-resolution gap | ### Evidence-Gap Priority | Priority | Gap | Rationale | |---|---|---| | P1 | cardiometabolic: conflict-resolution gap | 1 direct and 10 indirect sources; direction profile: mixed, negative, null, positive, unclear | | P2 | muscle function: conflict-resolution gap | 1 direct and 7 indirect sources; direction profile: mixed, null, positive, unclear | | P3 | safety and comorbidity: conflict-resolution gap | 0 direct and 2 indirect sources; direction profile: null, positive | | P4 | contextual adjacent evidence: conflict-resolution gap | 7 direct and 27 indirect sources; direction profile: mixed, negative, null, positive, unclear | ### Next-Study Design Recommendation The next high-yield study for Zone2 Training should target the **cardiometabolic** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 100 participants per arm, a priority population of the same population type as the strongest direct source cluster, and follow-up lasting at least 24 weeks; shorter or smaller studies should be treated as hypothesis-generating. ## Evidence Snapshot The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement. ### Load-Bearing Included Studies - Liu 2026; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=positive; representative statistic=P < 0.001. - Goncalves 2023; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=mixed; representative statistic=P < 0.001. - Goncalves 2024; tier=A1; directness=direct; endpoint=cardiometabolic; direction=positive; representative statistic=P < 0.001. - Jung 2020; tier=A1; directness=direct; endpoint=muscle function; direction=unclear; representative statistic=P = 0.018. - Goncalves 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.001. - Chen 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=mixed; representative statistic=P < 0.001. - Lapointe 2023; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=mixed; representative statistic=P = 0.003. - Nikoletou 2023; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.001. - Yu 2023b; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null. - Liang 2024; tier=B1; directness=review; endpoint=cardiometabolic; direction=unclear; representative statistic=P = 0.007. ### Source Classification Map Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement. - Liu 2026: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=positive; claims=145. - Goncalves 2023: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=mixed; claims=141. - Goncalves 2024: outcome=cardiometabolic; directness=direct; tier=A1; direction=positive; claims=109. - Jung 2020: outcome=muscle function; directness=direct; tier=A1; direction=unclear; claims=76. - Goncalves 2025: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=74. - Chen 2025: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=mixed; claims=67. - Lapointe 2023: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=mixed; claims=52. - Nikoletou 2023: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=27. - Yu 2023b: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=16. - Liang 2024: outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=138. - Li 2025a: outcome=cardiometabolic; directness=review; tier=B1; direction=mixed; claims=103. - Peng 2025: outcome=contextual adjacent evidence; directness=review; tier=B1; direction=positive; claims=77. - Chu 2026: outcome=contextual adjacent evidence; directness=review; tier=B1; direction=positive; claims=68. - Li 2022b: outcome=cardiometabolic; directness=review; tier=B1; direction=positive; claims=57. - Ren 2026: outcome=contextual adjacent evidence; directness=review; tier=B1; direction=unclear; claims=43. - Li 2026: outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=33. - Effects of High-Intensity Interval 2025: outcome=cardiometabolic; directness=review; tier=B1; direction=null; claims=8. - B Compare the Effects 2025: outcome=muscle function; directness=review; tier=B1; direction=mixed; claims=3. - Effects of High-intensity Interval 2023: outcome=muscle function; directness=review; tier=B1; direction=null; claims=3. - Effectiveness of High-intensity Interval 2024: outcome=muscle function; directness=review; tier=B1; direction=unclear; claims=2. - Impact of Low-Volume High-Intensity 2024: outcome=muscle function; directness=review; tier=B1; direction=positive; claims=2. - Yahat 2025: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=mixed; claims=419. - Neuendorf 2023: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=positive; claims=320. - Yu 2023a: outcome=muscle function; directness=review; tier=B2; direction=unclear; claims=239. - B 2024: outcome=cardiometabolic; directness=review; tier=B2; direction=unclear; claims=227. - Song 2024: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=226. - DAlleva 2023: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=mixed; claims=191. - Sun 2024: outcome=cardiometabolic; directness=indirect; tier=B2; direction=mixed; claims=184. - Li 2022a: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=negative; claims=169. - Faleiro 2025: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=165. - Zhang 2025a: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=150. - Gao 2025: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=negative; claims=127. - Youssef 2022: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=101. - Zheng 2025: outcome=muscle function; directness=review; tier=B2; direction=unclear; claims=99. - Schulte 2022: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=82. - Li 2025b: outcome=muscle function; directness=indirect; tier=B2; direction=unclear; claims=81. - Guo 2023: outcome=cardiometabolic; directness=review; tier=B2; direction=negative; claims=79. - Xie 2024: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=70. - Moon 2025: outcome=safety comorbidity; directness=indirect; tier=B2; direction=positive; claims=69. - Zhao 2025: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=68. ### Classification Criteria - **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices. - **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately. - **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else. - **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen. ### Load-Bearing Tensions - Severity 5 disagreement: Guo 2023 vs Li 2022b; Guo 2023 reports negative effect on cardiometabolic; Li 2022b reports positive on the same outcome — direct conflict - Severity 5 disagreement: Rohmansyah 2023 vs Gao 2025; Rohmansyah 2023 reports positive effect on contextual other; Gao 2025 reports negative on the same outcome — direct conflict - Severity 5 disagreement: Rohmansyah 2023 vs Li 2022a; Rohmansyah 2023 reports positive effect on contextual other; Li 2022a reports negative on the same outcome — direct conflict - Severity 5 disagreement: Neuendorf 2023 vs Gao 2025; Neuendorf 2023 reports positive effect on contextual other; Gao 2025 reports negative on the same outcome — direct conflict - Severity 5 disagreement: Neuendorf 2023 vs Li 2022a; Neuendorf 2023 reports positive effect on contextual other; Li 2022a reports negative on the same outcome — direct conflict - Severity 5 disagreement: Gao 2025 vs Peng 2025; Gao 2025 reports negative effect on contextual other; Peng 2025 reports positive on the same outcome — direct conflict - Severity 5 disagreement: Gao 2025 vs Chu 2026; Gao 2025 reports negative effect on contextual other; Chu 2026 reports positive on the same outcome — direct conflict - Severity 5 disagreement: Peng 2025 vs Li 2022a; Peng 2025 reports positive effect on contextual other; Li 2022a reports negative on the same outcome — direct conflict Additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Zhang 2026, Su 2025, Lin 2026, Zhang 2025b, Leahy 2022, Diego-Moreno 2022, Ahmadi 2025, Kosuta 2024. ## References - **Yahat 2025.** _Optimising adolescent health: a comparative study of high-intensity interval training and moderate-intensity continuous training on body composition and cardiovascular fitness in sedentary male youth._ Frontiers in Sports and Active Living, 2025. DOI: 10.3389/fspor.2025.1655906. PMID: 41210262. - **Neuendorf 2023.** _Effects of high-intensity interval training on functional performance and maximal oxygen uptake in comparison with moderate intensity continuous training in cancer patients: a systematic review and meta-analysis._ Supportive Care in Cancer, 2023. DOI: 10.1007/s00520-023-08103-9. PMID: 37851104. - **Yu 2023a.** _High-intensity interval training versus moderate-intensity continuous training on patient quality of life in cardiovascular disease: a systematic review and meta-analysis._ Scientific Reports, 2023. DOI: 10.1038/s41598-023-40589-5. PMID: 37626066. - **B 2024.** _Effects of high-intensity interval training versus moderate-intensity continuous training on vascular function among individuals with overweight and obesity—a systematic review._ International Journal of Obesity (2005), 2024. DOI: 10.1038/s41366-024-01586-4. PMID: 39080414. - **Song 2024.** _Comparative effects of high-intensity interval training and moderate-intensity continuous training on weight and metabolic health in college students with obesity._ Scientific Reports, 2024. DOI: 10.1038/s41598-024-67331-z. PMID: 39019997. - **DAlleva 2023.** _Effects of combined training or moderate intensity continuous training during a 3-week multidisciplinary body weight reduction program on cardiorespiratory fitness, body composition, and substrate oxidation rate in adolescents with obesity._ Scientific Reports, 2023. DOI: 10.1038/s41598-023-44953-3. PMID: 37848570. - **Sun 2024.** _Effect of eight-week high-intensity interval training versus moderate-intensity continuous training programme on body composition, cardiometabolic risk factors in sedentary adolescents._ Frontiers in Physiology, 2024. DOI: 10.3389/fphys.2024.1450341. PMID: 39183975. - **Li 2022a.** _A Comparative Study of Health Efficacy Indicators in Subjects with T2DM Applying Power Cycling to 12 Weeks of Low-Volume High-Intensity Interval Training and Moderate-Intensity Continuous Training._ Journal of Diabetes Research, 2022. DOI: 10.1155/2022/9273830. PMID: 35071605. - **Faleiro 2025.** _Isocaloric High-Intensity Interval and Circuit Training Increases Excess Post-Exercise Oxygen Consumption and Lipid Oxidation Compared to Moderate-Intensity Continuous Training._ Sports, 2025. DOI: 10.3390/sports13100355. PMID: 41150490. - **Zhang 2025a.** _Compared to moderate-intensity continuous training, short-term high-intensity interval training demonstrates enhanced effects on metabolic flexibility in adult males with obesity._ Journal of Exercise Science and Fitness, 2025. DOI: 10.1016/j.jesf.2025.07.005. PMID: 40799940. - **Liu 2026.** _Divergent effects of high-intensity functional training and moderate-intensity continuous training in adolescents with overweight/obesity: a randomized controlled trial on body composition, physical fitness, and psychological health._ Frontiers in Physiology, 2026. DOI: 10.3389/fphys.2026.1756285. PMID: 41918907. - **Goncalves 2023.** _Improving Health Outcomes in Coronary Artery Disease Patients with Short-Term Protocols of High-Intensity Interval Training and Moderate-Intensity Continuous Training: A Community-Based Randomized Controlled Trial._ Cardiovascular Therapeutics, 2023. DOI: 10.1155/2023/6297302. PMID: 38146531. - **Liang 2024.** _The impact of sprint interval training versus moderate intensity continuous training on blood pressure and cardiorespiratory health in adults: a systematic review and meta-analysis._ PeerJ, 2024. DOI: 10.7717/peerj.17064. PMID: 38495758. - **Gao 2025.** _Effects of high-intensity interval training versus moderate-intensity continuous training on cardiorespiratory and exercise capacity in patients with coronary artery disease: A systematic review and meta-analysis._ PLOS ONE, 2025. DOI: 10.1371/journal.pone.0314134. PMID: 39977401. - **Goncalves 2024.** _Effects of High-Intensity Interval Training vs Moderate-Intensity Continuous Training on Body Composition and Blood Biomarkers in Coronary Artery Disease Patients: A Randomized Controlled Trial._ Reviews in Cardiovascular Medicine, 2024. DOI: 10.31083/j.rcm2503102. PMID: 39076951. - **Li 2025a.** _Comparative effects of high-intensity interval training versus moderate-intensity continuous training on body composition and blood pressure in overweight adolescents: a systematic review and meta-analysis of randomized controlled trials._ Frontiers in Physiology, 2025. DOI: 10.3389/fphys.2025.1636792. PMID: 41103298. - **Youssef 2022.** _Clinical and Biological Adaptations in Obese Older Adults Following 12-Weeks of High-Intensity Interval Training or Moderate-Intensity Continuous Training._ Healthcare, 2022. DOI: 10.3390/healthcare10071346. PMID: 35885872. - **Zheng 2025.** _Effects and moderator of high-intensity interval training and moderate-intensity continuous training among children and adolescents with overweight or obese: a systematic review and meta-analysis._ Frontiers in Physiology, 2025. DOI: 10.3389/fphys.2025.1625516. PMID: 40809289. - **Schulte 2022.** _The Comparison of High-Intensity Interval Training Versus Moderate-Intensity Continuous Training after Coronary Artery Bypass Graft: A Systematic Review of Recent Studies._ Journal of Cardiovascular Development and Disease, 2022. DOI: 10.3390/jcdd9100328. PMID: 36286280. - **Li 2025b.** _Effects of high-intensity interval training and moderate-intensity continuous training on mitochondrial dynamics in human skeletal muscle._ Frontiers in Physiology, 2025. DOI: 10.3389/fphys.2025.1554222. PMID: 40313872. - **Guo 2023.** _Effect of High-Intensity Interval Training vs. Moderate-Intensity Continuous Training on Fat Loss and Cardiorespiratory Fitness in the Young and Middle-Aged a Systematic Review and Meta-Analysis._ International Journal of Environmental Research and Public Health, 2023. DOI: 10.3390/ijerph20064741. PMID: 36981649. - **Peng 2025.** _Effects of high-intensity interval training (HIIT) versus moderate-intensity continuous training (MICT) on cardiopulmonary function, body composition, and physical function in cancer survivors: a meta-analysis of randomized controlled trials._ Frontiers in Physiology, 2025. DOI: 10.3389/fphys.2025.1594574. PMID: 40584872. - **Jung 2020.** _Cardiorespiratory fitness and accelerometer-determined physical activity following one year of free-living high-intensity interval training and moderate-intensity continuous training: a randomized trial._ The International Journal of Behavioral Nutrition and Physical Activity, 2020. DOI: 10.1186/s12966-020-00933-8. PMID: 32102667. - **Goncalves 2025.** _Effects of High-Intensity Interval Training vs. Moderate-Intensity Continuous Training on Quality of Life and Mental Health in Post-Myocardial Infarction Patients: A Randomized Controlled Trial._ Portuguese Journal of Public Health, 2025. DOI: 10.1159/000545049. PMID: 40385518. - **Xie 2024.** _Effect of high-intensity interval training and moderate-intensity continuous training on blood lactate clearance after high-intensity test in adult men._ Frontiers in Physiology, 2024. DOI: 10.3389/fphys.2024.1451464. PMID: 39308979. - **Moon 2025.** _High-Intensity Interval Training Enhances Cardiovascular and Functional Outcomes Compared With Moderate-Intensity Continuous Training in Higher-Functioning Chronic Stroke._ Annals of Rehabilitation Medicine, 2025. DOI: 10.5535/arm.250098. PMID: 41492722. - **Zhao 2025.** _High-intensity interval training versus moderate-intensity continuous training for polycystic ovary syndrome: a meta-analysis of randomized controlled trials._ Frontiers in Endocrinology, 2025. DOI: 10.3389/fendo.2025.1672257. PMID: 41180193. - **Chu 2026.** _The effect of high-intensity interval training and moderate-intensity continuous training on cardiorespiratory function in healthy elderly individuals: Systematic review and meta-analysis._ Medicine, 2026. DOI: 10.1097/MD.0000000000047101. PMID: 41517714. - **Chen 2025.** _Effective of high-intensity interval training and moderate-intensity continuous training on body composition, glycolipid metabolism, and cardiopulmonary function in patients with pre-diabetes: a randomized controlled trial._ Frontiers in Endocrinology, 2025. DOI: 10.3389/fendo.2025.1614149. PMID: 40801034. - **Rohmansyah 2023.** _High-Intensity Interval Training Versus Moderate-Intensity Continuous Training for Improving Physical Health in Elderly Women._ Inquiry: A Journal of Medical Care Organization, Provision and Financing, 2023. DOI: 10.1177/00469580231172870. PMID: 37158072. - **Zhang 2026.** _Effects of slide-board-based high-intensity interval versus moderate-intensity continuous training on aerobic and anaerobic capacity in young speed skaters._ PLOS One, 2026. DOI: 10.1371/journal.pone.0343570. PMID: 41758881. - **Li 2022b.** _Effects of high-intensity interval training versus moderate-intensity continuous training on blood pressure in patients with hypertension: A meta-analysis._ Medicine, 2022. DOI: 10.1097/MD.0000000000032246. PMID: 36550888. - **Lapointe 2023.** _Addition of high-intensity interval training to a moderate intensity continuous training cardiovascular rehabilitation program after ischemic cerebrovascular disease: A randomized controlled trial._ Frontiers in Neurology, 2023. DOI: 10.3389/fneur.2022.963950. PMID: 36686521. - **Su 2025.** _Distinct lipidomic profiles but similar improvements in aerobic capacity following sprint interval training versus moderate-intensity continuous training in male adolescents._ Frontiers in Physiology, 2025. DOI: 10.3389/fphys.2025.1475391. PMID: 39949665. - **Lin 2026.** _Effects of high-intensity interval training versus moderate-intensity continuous training on cardiorespiratory function in patients after stroke: a systematic review and meta-analysis of randomized trials._ Frontiers in Neurology, 2026. DOI: 10.3389/fneur.2026.1727980. PMID: 41766998. - **Ren 2026.** _Comparative effectiveness of high-intensity interval training versus moderate-intensity continuous training in patients with type 2 diabetes mellitus: a systematic review and meta-analysis._ Frontiers in Endocrinology, 2026. DOI: 10.3389/fendo.2026.1833684. PMID: 42211454. - **Gu 2023.** _Effects of high intensity interval training versus moderate intensity continuous training on exercise capacity and quality of life in patients with heart failure: A systematic review and meta-analysis._ PLOS ONE, 2023. DOI: 10.1371/journal.pone.0290362. PMID: 37590312. - **Zhang 2025b.** _Influence of upper-body high-intensity intermittent training on energy metabolism and maximal oxygen uptake in elite swimmers._ Frontiers in Physiology, 2025. DOI: 10.3389/fphys.2025.1636405. PMID: 41030318. - **Liang 2026.** _A time-efficient public health strategy: a systematic review and meta-regression on the comparable and dose-independent effects of sprint interval training vs. moderate-intensity continuous training for metabolic health._ Frontiers in Public Health, 2026. DOI: 10.3389/fpubh.2025.1708893. PMID: 41567768. - **Leahy 2022.** _Changes in the Fitness Fatness Index following reduced exertion high-intensity interval training versus moderate-intensity continuous training in physically inactive adults._ Frontiers in Sports and Active Living, 2022. DOI: 10.3389/fspor.2022.961957. PMID: 35992158. - **Li 2026.** _Effects of high-intensity interval training on glycemic control and cardiometabolic risk factors in adults with prediabetes: a systematic review and meta-analysis._ Frontiers in Endocrinology, 2026. DOI: 10.3389/fendo.2026.1837386. PMID: 42222064. - **Cerini 2022.** _12 weeks high intensity interval training versus moderate intensity continuous training in chronic low back pain subjects: a randomised single-blinded feasibility study._ Archives of Physiotherapy, 2022. DOI: 10.1186/s40945-022-00136-3. PMID: 35491417. - **Nikoletou 2023.** _Comparison of high-intensity interval training versus moderate-intensity continuous training in pulmonary rehabilitation for interstitial lung disease: a randomised controlled pilot feasibility trial._ BMJ Open, 2023. DOI: 10.1136/bmjopen-2022-066609. PMID: 37607782. - **Diego-Moreno 2022.** _Acute Effects of High-Intensity Functional Training and Moderate-Intensity Continuous Training on Cognitive Functions in Young Adults._ International Journal of Environmental Research and Public Health, 2022. DOI: 10.3390/ijerph191710608. PMID: 36078324. - **Ahmadi 2025.** _Acute effects of high-intensity interval training and moderate-intensity continuous training on executive functions in healthy older adults._ Scientific Reports, 2025. DOI: 10.1038/s41598-025-91833-z. PMID: 40000786. - **Feng 2025.** _High-Intensity Interval Training and Moderate-Intensity Continuous Training Affect Running Economy in Endurance Runners: A Systematic Review and Meta-Analysis of Randomized Controlled Trials._ Journal of Human Kinetics, 2025. DOI: 10.5114/jhk/205427. PMID: 41766811. - **Yu 2023b.** _Effects of high-intensity interval training, moderate-intensity continuous training, and guideline-based physical activity on cardiovascular metabolic markers, cognitive and motor function in elderly sedentary patients with type 2 diabetes (HIIT-DM): a protocol for a randomized controlled trial._ Frontiers in Aging Neuroscience, 2023. DOI: 10.3389/fnagi.2023.1211990. PMID: 37649720. - **Kosuta 2024.** _Acute effects of high intensity interval training versus moderate intensity continuous training on haemostasis in patients with coronary artery disease._ Scientific Reports, 2024. DOI: 10.1038/s41598-024-52521-6. PMID: 38263210. - **Luo 2024.** _Effects of high intensity interval training and moderate intensity continuous training on enjoyment and affective responses in overweight or obese people: a meta-analysis._ Frontiers in Public Health, 2024. DOI: 10.3389/fpubh.2024.1487789. PMID: 39678233. - **Effects of High-Intensity Interval 2025.** _The Effects of High-Intensity Interval Training and Moderate-Intensity Continuous Training in Sedentary Individuals on Blood Pressure Reactivity._ Physiology, 2025. DOI: 10.1152/physiol.2025.40.s1.0878. - **Ahmad 2025.** _The effectiveness of high-intensity interval training versus moderate intensity continuous training in prehabilitation among patients undergoing major abdominal surgery: A study protocol._ PLOS One, 2025. DOI: 10.1371/journal.pone.0332361. PMID: 41071842. - **Effects of High-intensity Interval 2023.** _The effects of high-intensity interval training and moderate-to-vigorous intensity on cardiorespiratory fitness in patients with permanent or persistent atrial fibrillation._ European Journal of Preventive Cardiology, 2023. DOI: 10.1093/eurjpc/zwad125.186. - **B Compare the Effects 2025.** _<b>Compare the Effects of Pilates Training and Moderate-Intensity Continuous Training on Dyspnea and Cardiovascular Fitness in Hypertensive Patients</b>._ Journal of Health, Wellness, and Community Research, 2025. DOI: 10.61919/z1e92245. - **Effectiveness of High-intensity Interval 2024.** _Effectiveness of high-intensity interval training and moderate-intensity continuous training on cardiometabolic health in university labourers._ Wits Journal of Clinical Medicine, 2024. DOI: 10.18772/26180197.2024.v6n1a4. - **Impact of Low-Volume High-Intensity 2024.** _Impact of Low-Volume High-Intensity Interval Training and Moderate-Intensity Continuous Training on Physical Performance and Quality of Life among Postmenopausal Women._ Allied Medical Research Journal, 2024. DOI: 10.59564/amrj/02.01/009. ### Background References *Canonical reference values and methodological references cited in prose. Each entry's `citation_token` appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).* - **Tinetti 1988.** _Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. N Engl J Med. 1988;319(26):1701-1707._ DOI: 10.1056/NEJM198812293192604. PMID: 3205267. - **Ioannidis 2005.** _Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124._ (methodological reference) DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.
metadata
{
"article_type": "evidence_map",
"domain_slug": "longevity",
"researka_object_type": "submission",
"researka_submission_id": "c95fb1f9-da2a-4bb5-8b25-d68abdd9ad59",
"title": "Hypothesis-Generating Brief: Zone 2 training \u2014 full paper"
}